2. Search Result
Search Result
Results for "

active β-catenin

" in MedChemExpress (MCE) Product Catalog:

71

Inhibitors & Agonists

1

Screening Libraries

3

Fluorescent Dyes

3

Biochemical Assay Reagents

1

Peptides

18

Natural
Products

1

Isotope-Labeled Compounds

3

GMP Molecules

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-10182
    Laduviglusib
    Maximum Cited Publications
    295 Publications Verification

    CHIR-99021; CT99021

    		 Organoid GSK-3 Wnt β-catenin Autophagy Metabolic Disease Cancer
    Laduviglusib (CHIR-99021) is a potent, selective and orally active GSK-3α/β inhibitor with IC50s of 10 nM and 6.7 nM. Laduviglusib shows >500-fold selectivity for GSK-3 over CDC2, ERK2 and other protein kinases. Laduviglusib is also a potent Wnt/β-catenin signaling pathway activator. Laduviglusib enhances mouse and human embryonic stem cells self-renewal. Laduviglusib induces autophagy .
    Laduviglusib
  • HY-15244
    Alpelisib
    120+ Cited Publications

    BYL-719

    		 PI3K Apoptosis Cancer
    Alpelisib (BYL-719) is an orally active PI3Kα-selective inhibitor that blocks the conversion of PIP2 to PIP3, thereby inhibiting pathways including PI3K/AKT/mTOR, MAPK/ERK, Notch and JAK-STAT. Alpelisib also induces apoptosis, G0/G1 phase arrest and senescence; it significantly inhibits the proliferation, self-renewal, stemness and epithelial-mesenchymal transition (EMT) of tumor cells, reduces cancer stem cell populations and decreases the expression of stem cell markers. Alpelisib not only enhances the sensitivity to Eribulin (HY-13442) and exerts a synergistic effect with Paclitaxel (HY-B0015), but may also induce drug resistance by upregulating the SGK3/GSK3β/β-catenin signaling pathway. Alpelisib can be applied to research related to breast cancer, gastric cancer and lipomas associated with PTEN hamartoma tumor syndrome .
    Alpelisib
  • HY-N0527
    Pentagalloylglucose
    Maximum Cited Publications
    15 Publications Verification

    Penta-O-galloyl-β-D-glucose; 1,2,3,4,6-Pentagalloyl glucose

    		 JAK Keap1-Nrf2 Apoptosis β-catenin Reactive Oxygen Species (ROS) E1/E2/E3 Enzyme Neurological Disease Inflammation/Immunology Cancer
    Pentagalloylglucose (Penta-O-galloyl-β-D-glucose) is an orally active gallic tannin compound and an inducer of apoptosis and autophagy. Pentagalloglucose induces cell apoptosis and autophagy through the GSK3β/β-catenin pathway. Pentagalloylglucose inhibits UBE2T-mediated p53 ubiquitination, upregulates p53, downregulates RRM1/RRM2 in pancreatic cancer organoids. Pentagalloglucose has antioxidant, anti mutagenic, anti-inflammatory, anticonvulsant, cardioprotective, anti allergic, cholesterol lowering, and anti-tumor activities .
    Pentagalloylglucose
  • HY-147245
    Basroparib

    STP1002

    		 PARP Cancer
    Basroparib (STP1002) is a selective, orally active inhibitor of tankyrase (TNKS1/TNKS2) with IC50 of 29.94 nM and 3.68 nM for TNKS1 and TNKS2, respectively. Basroparib has an IC50 of >10 μM for PARP1. Basroparib binds to TNKS, stabilizes AXIN1/2 proteins, blocks Wnt/β-catenin signaling pathway, inhibits tumor cell proliferation and induces apoptosis, while reducing cancer stem cell properties. Basroparib can be used in colorectal cancer (CRC) studies with KRAS mutations (such as G12V/G12D) to overcome acquired resistance to MEK inhibitors. STP1002 has synergistic antitumor activity with MEK inhibitors .
    Basroparib
  • HY-10456
    TAK-715
    10+ Cited Publications

    		 p38 MAPK Casein Kinase Wnt Inflammation/Immunology
    TAK-715 is an orally active and potent p38 MAPK inhibitor with IC50s of 7.1 nM, 200 nM for p38α and p38β, respectively. TAK-715 inhibits casein kinase I (CK1δ/ε) to regulate activation of Wnt/β-catenin signaling. TAK-715 shows good significant efficacy in a rat arthritis model .
    TAK-715
  • HY-N7030
    5,7,3',4'-Tetramethoxyflavone
    2 Publications Verification

    		 Fungal Parasite Bacterial Infection
    5,7,3',4'-Tetramethoxyflavone, an orally active polymethoxyflavones (PMFs) that can be isolated from M. exotica, possesses various bioactivities, including anti-fungal, anti-malarial, anti-mycobacterial, and anti-inflammatory activities. 5,7,3',4'-Tetramethoxyflavone exhibits chondroprotective activity by targeting β-catenin signaling .
    5,7,3',4'-Tetramethoxyflavone
  • HY-14930
    Mirodenafil

    SK3530

    		 Phosphodiesterase (PDE) Glucocorticoid Receptor Wnt β-catenin Apoptosis Neurological Disease Inflammation/Immunology Endocrinology
    Mirodenafil (SK3530) is an orally active, potent, reversible, and selective phosphodiesterase 5 (PDE5) inhibitor. Mirodenafil is a glucocorticoid receptor (GR) modulator Mirodenafil activates the Wnt/β-catenin signaling pathway by downregulating Dkk1 expression. Mirodenafil can be used for the research of erectile dysfunction (ED), Alzheimer’s disease (AD) and systemic sclerosis (SSc) .
    Mirodenafil
  • HY-W013812
    Ethyl linoleate

    Linoleic Acid ethyl ester; Mandenol

    		 Tyrosinase Akt GSK-3 β-catenin Biochemical Assay Reagents NF-κB Heme Oxygenase (HO) Cardiovascular Disease Inflammation/Immunology
    Ethyl linoleate (Linoleic Acid ethyl ester) is an orally active unsaturated fatty acid. Ethyl linoleate inhibits the Akt/GSK3β/β-catenin signaling pathway and the activation of NF-κB. Ethyl linoleate induces heme oxygenase-1 and inhibits tyrosinase. Ethyl linoleate has whitening and anti-inflammatory effects. Ethyl linoleate promotes compound absorption. Ethyl linoleate has a significant influence on atherosclerosis. Ethyl linoleate is used in the research of inflammatory diseases. Ethyl linoleate can be used in cosmetics
    Ethyl linoleate
  • HY-113283
    Homogentisic acid

    		Amyloid-β Natriuretic Peptide Receptor (NPR) α-synuclein Transthyretin (TTR) Claudin Neurological Disease Metabolic Disease Cancer
    Homogentisic acid is an orally active, blood-brain barrier-permeable amyloidogenic compound that functions as both an amyloid component and a pigment precursor. Accumulation of homogentisic acid downregulates tight junction proteins (such as claudin-5, occludin, ZO-1) and impairs blood-brain barrier integrity. Homogentisic acid and its oxidation product benzoquinone acetic acid not only induce the aggregation and fibrosis of multiple proteins (such as Aβ1-42, α-synuclein, SAA, Transthyretin (TTR), atrial natriuretic peptide), but also trigger oxidative stress, damage to the Wnt/β-catenin pathway, and neurotoxicity, leading to ochronosis pigment deposition and synaptic dysfunction. At specific concentrations, homogentisic acid exerts no cytotoxicity or genotoxicity on human peripheral blood lymphocytes, and even counteracts the genotoxicity induced by Irinotecan (HY-16562). Homogentisic acid serves as an important tool molecule for investigating the mechanisms of diseases including ochronosis, secondary amyloidosis, Alzheimer's disease, and colorectal cancer .
    Homogentisic acid
  • HY-N0559
    Kirenol
    1 Publications Verification

    		 Casein Kinase Apoptosis AMPK Akt NF-κB TGF-beta/Smad Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    Kirenol is a diterpenoid compound, an orally active apoptosis inducer and signaling pathway regulator, with a Kd value of 5.47 μM against the target CK2. Kirenol promotes the cleavage of Bid into tBid, regulates the protein levels/phosphorylation of Bax, Bcl-2, p53 and p21, and induces caspase-independent apoptosis, S-phase cell cycle arrest, ROS accumulation and cytotoxicity in cancer cells. Kirenol activates the CK2/AKT and AMPK-mTOR-ULK1 pathways, inhibits the signaling of NF-κB, TGF-β/Smads and NLRP3 inflammasome, and regulates the GSK3β, BMP and Wnt/β-catenin pathways. Kirenol induces autophagy, mitophagy and osteoblast differentiation, promotes mitochondrial fusion, and exerts antioxidant, anti-inflammatory, antifibrotic, renoprotective, cardioprotective, neuroprotective and analgesic effects. Kirenol is applicable to research related to chronic myeloid leukemia, ischemic stroke, diabetic nephropathy, heart failure, acute lung injury and osteoporosis .
    Kirenol
  • HY-111386
    E-7386

    		Epigenetic Reader Domain Cancer
    E-7386 is an orally active CBP/beta-catenin modulator.
    E-7386
  • HY-123611
    Supinoxin

    RX-5902

    		 DNA/RNA Synthesis Apoptosis Cancer
    Supinoxin (RX-5902) is an orally active inhibitor of phosphorylated-p68 RNA helicase (P-p68) and a potent first-in-class anti-cancer agent. Supinoxin interacts with Y593 phosphorylated-p68 and attenuates the nuclear shuttling of β-catenin. Supinoxin induces cell apoptosis and inhibits growth of TNBC cancer cell lines with IC50s ranging from 10 nM to 20 nM .
    Supinoxin
  • HY-108527
    CD1530
    3 Publications Verification

    		 RAR/RXR Bacterial TGF-beta/Smad β-catenin MMP Reactive Oxygen Species (ROS) Infection Metabolic Disease Endocrinology
    CD1530 is an orally active, selective RARγ agonist and antibacterial agent. CD1530 reduces Smad1/5/8 phosphorylation and overall Smad levels. CD1530 reduces β-catenin, MMP9 protein, and ROS levels. CD1530 exhibits activities such as inhibiting heterotopic ossification, promoting Achilles tendon healing, and inhibiting muscle fatty infiltration. CD1530 can be used in the research of orthopedic diseases (such as heterotopic ossification, Achilles tendon injury), muscle diseases (such as muscle fatty infiltration-related diseases) .
    CD1530
  • HY-N0432
    Astragaloside I

    Astrasieversianin IV; Cyclosieversioside B

    		 Wnt β-catenin Metabolic Disease
    Astragaloside I, one of the main active ingredients in Astragalus membranaceus, has osteogenic properties. Astragaloside I stimulates osteoblast differentiation through activating the Wnt/β-catenin signaling pathway .
    Astragaloside I
  • HY-123851
    MSC2504877

    M2912

    		 PARP Cancer
    MSC2504877 (M2912) is a potent and orally active tankyrase inhibitor with IC50s of 0.0007, 0.0008, 0.54 µM for TNKS, TNKS2, PARP1, respectively. MSC2504877 increases the expression of AXIN2 and TNKS protein levels and decreases β-catenin levels. MSC2504877 shows anti-tumor activity .
    MSC2504877
  • HY-137849
    RK-582

    		PARP Cancer
    RK-582 is a tankyrase inhibitor, antitumor agent, and orally bioavailable growth inhibitor, with an IC50 of 36.1 nM against human tankyrase-1 and an IC50 of 39.2 nM against human tankyrase-2. In APC-mutated colorectal cancer cells, the sensitivity to RK-582 correlates with the level of active β-catenin, while drug resistance associates with PIK3CA mutation. RK-582 can be used for the research of colorectal cancer .
    RK-582
  • HY-145267
    OM-153

    		PARP Wnt Cancer
    OM-153 is a potent and orally active tankyrase inhibitor with IC50s of 13 nM and 2 nM for tankyrase 1 and tankyrase 2 (TNKS1/2), respectively. OM-153 inhibits luciferase-based Wnt/β-catenin signaling reporter activity with an IC50 value of 0.63 nM. OM-153 shows inhibition of Wnt/β-catenin signaling and proliferation in COLO 320DM .
    OM-153
  • HY-129566
    Withanolide B

    		ERK Wnt β-catenin RUNX Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    Withanolide B is an active component of W. somnifera Dunal. Withanolide B promotes osteogenic differentiation of hBMSCs via ERK1/2 and Wnt/β-catenin signaling pathways. Withanolide B exhibits neuroprotective, anti-arthritic, anti-aging and anti-cancer effects .
    Withanolide B
  • HY-14930A
    Mirodenafil dihydrochloride

    SK-3530 dihydrochloride

    		 Phosphodiesterase (PDE) Glucocorticoid Receptor Wnt β-catenin Apoptosis Neurological Disease Inflammation/Immunology Endocrinology
    Mirodenafil (SK3530) dihydrochloride is an orally active, potent, reversible, and selective phosphodiesterase 5 (PDE5) inhibitor. Mirodenafil dihydrochloride is a glucocorticoid receptor (GR) modulator Mirodenafil dihydrochloride activates the Wnt/β-catenin signaling pathway by downregulating Dkk1 expression. Mirodenafil dihydrochloride can be used for the research of erectile dysfunction (ED), Alzheimer’s disease (AD) and systemic sclerosis (SSc) .
    Mirodenafil dihydrochloride
  • HY-131447
    KY19382
    4 Publications Verification

    A3051

    		 GSK-3 Wnt β-catenin Metabolic Disease
    KY19382 is a potent and orally active dual inhibitor of CXXC5-DVL and GSK3β, with IC50s of 19 and 10 nM, respectively. KY19382 activates Wnt/β-catenin signaling through inhibitory effects on both CXXC5-DVL interaction and GSK3β activity. KY19382 can be used for the research of high fat diet (HFD) induced metabolic diseases .
    KY19382
  • HY-145669
    DIF-3
    5+ Cited Publications

    		 Wnt CDK GSK-3 Infection Cancer
    DIF-3 is an orally active anticancer agent. DIF-3 reduces the expression levels of cyclin D1 and c-Myc by facilitating their degradation via activation of GSK-3β. DIF-3 inhibits Wnt/β-catenin signaling pathway-related proteins in cells. DIF-3 induces reactive oxygen species (ROS) and autophagy. DIF suppresses the growth of Trypanosoma. cruzi in HT1080 cells. DIF-3 exerts antitumor effects both in vitro and in vivo .
    DIF-3
  • HY-15244A
    Alpelisib hydrochloride
    120+ Cited Publications

    BYL-719 hydrochloride

    		 PI3K Apoptosis Cancer
    Alpelisib (BYL-719) hydrochloride is an orally active PI3Kα-selective inhibitor that blocks the conversion of PIP2 to PIP3, thereby inhibiting pathways including PI3K/AKT/mTOR, MAPK/ERK, Notch and JAK-STAT. Alpelisib hydrochloride also induces apoptosis, G0/G1 phase arrest and senescence; it significantly inhibits the proliferation, self-renewal, stemness and epithelial-mesenchymal transition (EMT) of tumor cells, reduces cancer stem cell populations and decreases the expression of stem cell markers. Alpelisib hydrochloride not only enhances the sensitivity to Eribulin (HY-13442) and exerts a synergistic effect with Paclitaxel (HY-B0015), but may also induce drug resistance by upregulating the SGK3/GSK3β/β-catenin signaling pathway. Alpelisib hydrochloride can be applied to research related to breast cancer, gastric cancer and lipomas associated with PTEN hamartoma tumor syndrome .
    Alpelisib hydrochloride
  • HY-70005
    CPA inhibitor
    3 Publications Verification

    Carboxypeptidase inhibitor

    		 Carboxypeptidase Wnt β-catenin Inflammation/Immunology
    CPA inhibitor (Compound 5) (Carboxypeptidase inhibitor) is an orally active competitive carboxypeptidase A (CPA) inhibitor with a Ki value of 0.32 μM. CPA inhibitor blocks the activity of carboxypeptidase A3 (CPA3). CPA activator activates the Wnt/Lrp6/β-catenin signaling pathway. CPA inhibitor reduces epithelial damage. CPA inhibitor is applicable to research related to inflammatory bowel disease, including ulcerative colitis and Crohn's disease .
    CPA inhibitor
  • HY-164478
    G-631

    		PARP Wnt β-catenin Cancer
    G-631 is an orally active tankyrase(TNKS1/TNKS2) inhibitor. G-631 stabilizes AXIN and inhibits the Wnt/β-catenin signaling pathway. G-631 can be used in studies related to cancers such as colorectal cancer .
    G-631
  • HY-132300
    ZW4864

    		β-catenin Cancer
    ZW4864 is an orally active and selective β catenin/B-Cell lymphoma 9 protein protein interaction (β catenin/BCL9 PPI) inhibitor. ZW4864 inhibits β catenin/BCL9 PPI with a Ki value of 0.76 μM and an IC50 value of 0.87 μM .
    ZW4864
  • HY-N1457
    Chrysosplenetin
    3 Publications Verification

    		 P-glycoprotein Topoisomerase Apoptosis DNA/RNA Synthesis Wnt β-catenin Parasite Infection Metabolic Disease Cancer
    Chrysosplenetin is an orally active polymethoxyflavone. Chrysosplenetin exerts anticancer effects by inhibiting topoisomerase, protecting DNA and inducing apoptosis. Chrysosplenetin acts as an antimalarial sensitizer, reverses Artemisinin (HY-B0094) resistance by inhibiting and downregulating P-glycoprotein, and enhances the efficacy of Artemisinin. Chrysosplenetin promotes bone formation by activating the Wnt/β-catenin pathway and exerts anti-osteoporotic effects .
    Chrysosplenetin
  • HY-10182R
    Laduviglusib (Standard)

    CHIR-99021 (Standard); CT99021 (Standard)

    		 Organoid GSK-3 Autophagy Wnt β-catenin Reference Standards Cancer
    Laduviglusib (Standard) is the analytical standard of Laduviglusib. Laduviglusib (CHIR-99021) is a potent, selective and orally active GSK-3α/β inhibitor with IC50s of 10 nM and 6.7 nM. Laduviglusib shows >500-fold selectivity for GSK-3 over CDC2, ERK2 and other protein kinases. Laduviglusib is also a potent Wnt/β-catenin signaling pathway activator. Laduviglusib enhances mouse and human embryonic stem cells self-renewal. Laduviglusib induces autophagy .
    Laduviglusib (Standard)
  • HY-108442
    JW67
    1 Publications Verification

    		 Wnt Cancer
    JW67 inhibits the canonical Wnt signaling with an IC50 of 1.17μM . JW67 affects the multiprotein complex consisting of β-catenin/GSK-3β/AXIN/APC/CK1 that rapidly reduces active β-catenin with a subsequent downregulation of Wnt target genes. JW67 also inhibits colorectal cancer cell growth .
    JW67
  • HY-172920
    Wnt/β-catenin-IN-6

    		Wnt β-catenin EGFR ERK COX Akt GSK-3 c-Myc Apoptosis Interleukin Related JNK Inflammation/Immunology Cancer
    Wnt/β-catenin-IN-6 is an orally active Wnt/β-catenin pathway inhibitor. Wnt/β-catenin-IN-6 blocks the AKT/GSK-3β/β-catenin signaling pathway, leading to reduced expression of Wnt target genes (c-Myc, c-Jun). Wnt/β-catenin-IN-6 reduces COX2 expression and IL-8 levels, highlighting its dual anti-inflammatory and antitumor effects. Wnt/β-catenin-IN-6 can induce apoptosis. Wnt/β-catenin-IN-6 serves as a tool for non-small cell lung cancer (NSCLC) research .
    Wnt/β-catenin-IN-6
  • HY-W142432
    Perfluoroundecanoic acid

    		Biochemical Assay Reagents β-catenin Wnt Arginase TGF-beta/Smad mTOR Akt ERK Atg8/LC3 p62 Autophagy Metabolic Disease Inflammation/Immunology Cancer
    Perfluoroundecanoic acid is a perfluoroalkyl substance (PFAS). Perfluoroundecanoic acid is an orally active oxidative stress inducer. Perfluoroundecanoic acid promotes macrophage M2 polarization, activates Wnt/β-catenin signaling and enhances β-catenin nuclear accumulation. Perfluoroundecanoic acid -induced M2 phenotype macrophage accelerates tumor progression in vitro and in vivo. Perfluoroundecanoic acid induces DNA damage, reproductive and pathophysiological dysfunctions via oxidative stress in male Swiss mice. Perfluoroundecanoic acid inhibits Leydig cell development in pubertal male rats via inducing oxidative stress and autophagy. Perfluoroundecanoic acid accelerates insulitis development in a mouse model of type 1 diabetes. Perfluoroundecanoic acid can be used for the study of ovarian cancer, type 1 diabetes and inflammation .
    Perfluoroundecanoic acid
  • HY-D1474
    WNT7A-IN-1 sodium

    		Wnt Cancer
    WNT7A-IN-1 sodium (1365-0109), a WNT7A inhibitor, disrupts the protein-protein interaction between WNT7A and its receptor FZD5, resulting in the upregulation of MHC-I expression. WNT7A-IN-1 sodium significantly increases the expression of MHC-I and p-p65,while concurrently reducing the expression of active β-catenin . WNT7A-IN-1 sodium (compound F) is also a photographic sensitizer in the green spectral region .
    WNT7A-IN-1 sodium
  • HY-N0899
    Wilforine

    		JAK STAT Wnt β-catenin Inflammation/Immunology Cancer
    Wilforine is an orally active JAK-STAT pathway inhibitor with immunomodulatory effects and the ability to inhibit osteoclast fusion. Wilforine disrupts lipid raft integrity, reprograms cholesterol and glycosphingolipid metabolic pathways, regulates NF-κB and the complement system, and modulates the expression of various interleukins. Wilforine also inhibits the Wnt11/β-catenin signaling pathway and suppresses the proliferation of fibroblast-like synoviocytes. Wilforine can serve as a quality and pharmacokinetic marker for Tripterygium glycoside tablets, and can be applied to research on related diseases such as rheumatoid arthritis, inflammatory osteolysis, and SAPHO syndrome .
    Wilforine
  • HY-N0909
    Notoginsenoside R2
    1 Publications Verification

    20(S)-Notoginsenoside R2; Ginsenoside Ng-R2

    		 Apoptosis MEK ERK Reactive Oxygen Species (ROS) Caspase COX β-catenin Src MDM-2/p53 JAK STAT Neurological Disease Metabolic Disease Inflammation/Immunology
    Notoginsenoside R2 (20(S)-Notoginsenoside R2; Ginsenoside Ng-R2) is an orally active notoginsenoside . Notoginsenoside R2 activates P90RSK and Nrf2 via the MEK1/2-ERK1/2 pathway to inhibit 6-OHDA-induced apoptotic damage in nerve cells. Notoginsenoside R2 upregulates SOX8/β-catenin by reducing miR-27a, thereby suppressing Aβ25-35-induced neuronal apoptosis and inflammatory responses . Notoginsenoside R2 alleviates lipid accumulation and mitochondrial dysfunction in diabetic nephropathy by inhibiting c-Src. Notoginsenoside R2 alleviates hepatic fibrosis by inducing hepatic stellate cell senescence and inhibiting the inflammatory microenvironment via JAK/STAT3 suppression . Notoginsenoside R2 can be used in research related to Parkinson's disease, Alzheimer's disease, diabetic nephropathy and hepatic fibrosis .
    Notoginsenoside R2
  • HY-112799
    DK419

    		Wnt β-catenin c-Myc CDK Survivin Cancer
    DK419 is a potent and orally active Wnt/β-catenin signaling inhibitor, with an IC50 of 0.19 μM. DK419 reduces protein lelvels of Axin2, β-catenin, c-Myc, Cyclin D1 and Survivin and induces production of pAMPK .
    DK419
  • HY-170411
    WNT7A-IN-1

    		Wnt Cancer
    WNT7A-IN-1 (1365-0109), a WNT7A inhibitor, disrupts the protein-protein interaction between WNT7A and its receptor FZD5, resulting in the upregulation of MHC-I expression. WNT7A-IN-1 significantly increases the expression of MHC-I and p-p65,while concurrently reducing the expression of active β-catenin. WNT7A-IN-1 (compound F) is also a photographic sensitizer in the green spectral region .
    WNT7A-IN-1
  • HY-132300A
    ZW4864 free base

    		β-catenin Cancer
    ZW4864 (free base) is an orally active and selective β catenin/B-Cell lymphoma 9 protein protein interaction (β catenin/BCL9 PPI) inhibitor. ZW4864 (free base) inhibits β catenin/BCL9 PPI with a Ki value of 0.76 μM and an IC50 value of 0.87 μM .
    ZW4864 free base
  • HY-18006
    NKP608
    1 Publications Verification

    		 Neurokinin Receptor Wnt Bcl-2 Family β-catenin Cyclin G-associated Kinase (GAK) VEGFR Caspase Cadherin Apoptosis Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    NKP608 is a non-peptidic derivative of 4-aminopiperidine, a highly selective, orally active, neurokinin-1 (NK1) receptor antagonist with IC50 of 2.6 nM. NKP608 is active both in vitro and in vivo, showing extremely low affinity for NK2, NK3 receptors. NKP608 exerts its effects by blocking the NK₁ receptor, regulate cell proliferation and apoptosis, affect neurotransmitter functions and gastric mucosal repair mechanisms, and suppress the Wnt/β-catenin pathway in antitumor research. NKP608 is applicable to research related to various diseases, including cough, anxiety disorders, depression, gastric mucosal injury, and colorectal cancer .
    NKP608
  • HY-173482
    TFAP4/Wnt/β-catenin-IN-1

    		Wnt β-catenin Cancer
    TFAP4/Wnt/β-catenin-IN-1 (Compound A61) is an orally active TFAP4/Wnt/β-catenin inhibitor. TFAP4/Wnt/β-catenin-IN-1 has significant anticancer activity against a variety of cancer cells (such as gastric cancer, lung cancer, breast cancer, etc.), and has the strongest anticancer activity against MGC-803 gastric cancer cells (IC50: 3.92 μM). TFAP4/Wnt/β-catenin-IN-1 induces apoptosis and cell cycle arrest (S phase) in cancer cells by inhibiting the TFAP4/Wnt/β-catenin signaling pathway. TFAP4/Wnt/β-catenin-IN-1 can be used in the study of gastric cancer .
    TFAP4/Wnt/β-catenin-IN-1
  • HY-10182C
    Laduviglusib dihydrochloride

    CHIR-99021 dihydrochloride; CT99021 dihydrochloride

    		 GSK-3 β-catenin Wnt Autophagy Organoid Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    Laduviglusib dihydrochloride (CHIR-99021 dihydrochloride; CT99021 dihydrochloride) is a potent, selective and orally active GSK-3α/β inhibitor with IC50s of 10 nM and 6.7 nM. Laduviglusib dihydrochloride shows >500-fold selectivity for GSK-3 over CDC2, ERK2 and other protein kinases. Laduviglusib dihydrochloride is also a potent Wnt/β-catenin signaling pathway activator. Laduviglusib dihydrochloride enhances mouse and human embryonic stem cells self-renewal. Laduviglusib dihydrochloride induces autophagy .
    Laduviglusib dihydrochloride
  • HY-117738
    Benarthin

    		Aminopeptidase Endogenous Metabolite GSK-3 β-catenin Apoptosis Metabolic Disease
    Benarthin is an orally active Pyroglutamyl peptidase inhibitor, THY1 inhibitor (with a Kd value of 5.13e-08 M) and competitive PGP-1 inhibitor (Ki = 1.2 µM). Benarthin is isolated from the culture broth of Streptomyces xanthophaeus MJ244-SF1. Benarthin disrupts the THY1-SFRP1 interaction, inhibits the activation of the GSK3α/β-β-catenin pathway, and reduces the upregulation of FASLG. Benarthin attenuates urothelial anoikis and reduces cell Apoptosis. Benarthin possesses iron-chelating activity. Benarthin maintains urothelial barrier integrity and blocks the pathological cascade of renal interstitial fibroblasts induced by HAP stimulation. Benarthin can be used in studies related to kidney stones .
    Benarthin
  • HY-155705
    BMP agonist 1

    		TGF-β Receptor GSK-3 β-catenin Others
    BMP agonist 1 (compound 2 b) is a small-molecule agonist of bone morphogenic protein (BMP). BMP induces C2C12 cell differentiation with BMP and highly depends on active BMP signaling. BMP agonist 1 inhibits GSK3β, increases β-catenin signaling and synergistically regulates Id2and Id3 expression. BMP agonist 1 is used in diseases and defects of the skeleton research .
    BMP agonist 1
  • HY-N10359
    Isoandrographolide

    		NOD-like Receptor (NLR) Caspase Akt GSK-3 β-catenin Metabolic Disease Inflammation/Immunology Cancer
    Isoandrographolide is an orally active NLRP3 inflammasome inhibitor and AKT/GSK-3β/β-catenin pathway inhibitor. Isoandrographolide inhibits the expression of NLRP3, ASC, and caspase-1, and reduces the levels of phosphorylated AKT, phosphorylated GSK-3β, and β-catenin. Isoandrographolide alleviates inflammatory responses, reduces collagen deposition, suppresses epithelial-mesenchymal transition (EMT), induces differentiation of leukemia cells, inhibits the growth of leukemia cells, protects lung and kidney tissues, regulates cytokine levels, and also exhibits hepatoprotective effects. Isoandrographolide can be used in studies related to silicosis, murine myeloid leukemia, renal tubulointerstitial fibrosis, and non-alcoholic fatty liver disease .
    Isoandrographolide
  • HY-13675
    ME-143

    NV-143

    		 Wnt Endogenous Metabolite Cancer
    ME-143 is a second-generation tumor-specific inhibitor of NADH oxidase. ME-143 inhibits the WNT/β-catenin pathway in colorectal cancer cells. ME-143 has broadly active against cancers in vitro and in vivo .
    ME-143
  • HY-14930R
    Mirodenafil (Standard)

    SK3530 (Standard)

    		 Phosphodiesterase (PDE) Glucocorticoid Receptor Wnt β-catenin Apoptosis Reference Standards Neurological Disease Inflammation/Immunology Endocrinology
    Mirodenafil (Standard) is the analytical standard of Mirodenafil. This product is intended for research and analytical applications. Mirodenafil (SK3530) is an orally active, potent, reversible, and selective phosphodiesterase 5 (PDE5) inhibitor. Mirodenafil is a glucocorticoid receptor (GR) modulator Mirodenafil activates the Wnt/β-catenin signaling pathway by downregulating Dkk1 expression. Mirodenafil can be used for the research of erectile dysfunction (ED), Alzheimer’s disease (AD) and systemic sclerosis (SSc) .
    Mirodenafil (Standard)
  • HY-179339
    LSD1-IN-46

    		Histone Demethylase Cancer
    LSD1-IN-46 is a potent and orally active Lysine-specific demethylase 1 (LSD1) inhibitor with an IC50 of 0.082 μM. LSD1-IN-46 interrupts the β-catenin-mediated transcriptional program, thereby suppressing the stemness of gastric cancer cells. LSD1-IN-46 exhibits strong anti-tumor activity. LSD1-IN-46 can be used for the research of gastric cancer .
    LSD1-IN-46
  • HY-N0527R
    Pentagalloylglucose (Standard)

    Penta-O-galloyl-β-D-glucose (Standard); 1,2,3,4,6-Pentagalloyl glucose (Standard)

    		 Reference Standards JAK Keap1-Nrf2 Apoptosis β-catenin Reactive Oxygen Species (ROS) Neurological Disease Inflammation/Immunology Cancer
    Pentagalloylglucose (Standard) is the analytical standard of Pentagalloylglucose. This product is intended for research and analytical applications. Pentagalloylglucose (Penta-O-galloyl-β-D-glucose) is an orally active gallic tannin compound and an inducer of apoptosis and autophagy. Pentagalloglucose induces cell apoptosis and autophagy through the GSK3β/β-catenin pathway. Pentagalloylglucose inhibits UBE2T-mediated p53 ubiquitination, upregulates p53, downregulates RRM1/RRM2 in pancreatic cancer organoids. Pentagalloglucose has antioxidant, anti mutagenic, anti-inflammatory, anticonvulsant, cardioprotective, anti allergic, cholesterol lowering, and anti-tumor activities .
    Pentagalloylglucose (Standard)
  • HY-168924
    Wnt/β-catenin activator 1

    		Wnt β-catenin Metabolic Disease
    Wnt/β-catenin activator 1 (Compound 5m) is the orally active activator for Wnt/β-catenin signaling pathway, that arrests cell cycle at G1 phase, inhibits early proliferation of adipocytes, and inhibits adipogenesis in cell 3T3-L1 with an IC50 of 330 nM. Wnt/β-catenin activator 1 exhibits anti-adipogenic and anti-dyslipidemic activities in high-fat diet fed Syrian golden hamster model .
    Wnt/β-catenin activator 1
  • HY-176057
    S118

    		β-catenin Inflammation/Immunology
    S118 is an orally active sphingosine-1-phosphate receptor 2 (S1P2 receptor) inhibitor. S118 prevents the binding of the S1P2 receptor to dapper1 (Dpr1), reduces the accumulation of β-catenin and blocks the nuclear translocation of the S1P2 receptor, thereby inhibiting inflammation, fibrosis, and epithelial-mesenchymal transition (EMT) and exerting anti-idiopathic pulmonary fibrosis (IPF) activity. S118 is promising for research of idiopathic pulmonary fibrosis .
    S118
  • HY-N0432R
    Astragaloside I (Standard)

    Astrasieversianin IV (Standard); Cyclosieversioside B (Standard)

    		 Reference Standards Wnt β-catenin Metabolic Disease
    Astragaloside I (Standard) is the analytical standard of Astragaloside I. This product is intended for research and analytical applications. Astragaloside I, one of the main active ingredients in Astragalus membranaceus, has osteogenic properties. Astragaloside I stimulates osteoblast differentiation through the Wnt/β-catenin signaling pathway .
    Astragaloside I (Standard)
  • HY-N0008R
    Orcinol glucoside (Standard)

    		Reference Standards Wnt Neurological Disease
    Orcinol glucoside (Standard) is the analytical standard of Orcinol glucoside. This product is intended for research and analytical applications. Orcinol glucoside (OG) is an active constituent isolated from Curculigo orchioides, with antidepressant effects. Orcinol glucoside facilitates the shift of MSC fate to osteoblast and prevents adipogenesis via Wnt/β-catenin signaling pathway .
    Orcinol glucoside (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: